摘要
目的：通过观察香砂六君子丸对脾虚痰浊大鼠肝脏JAK2/STAT3/Bcl-2途径的影响,探讨健脾化痰法防控肥胖人群罹患肝病风险的可能性。方法：40只雄性SD大鼠,随机分为对照组、脾虚痰浊组（模型组）、香砂六君丸低剂量治疗组（香低组）、香砂六君丸中剂量治疗组（香中组）和香砂六君丸高剂量治疗组（香高组）,每组8只;ELISA法检测肝组织谷丙转氨酶（GPT）和谷草转氨酶（GOP）水平、血清超氧化物岐化酶（SOD）、丙二醛（MDA）和脂多糖（LPS）浓度以及谷胱甘肽过氧化物酶（GSH-Px）活性;免疫组化法检测肝组织磷酸化（p）-JAK2、p-STAT3和Bcl-2表达。结果：与对照组比较,模型组GPT、GOT、MDA和LPS水平上升,SOD水平和GSH-Px活性下降,p-JAK2/STAT3表达上升,Bcl-2表达下降,均有统计学意义;与模型组比较,后2组GPT、GOT和MDA以及后3组的LPS水平下降,但后3组的SOD水平和GSH-Px活性上升,香高组的p-JAK2和后2组的p-STAT3表达下降,香高组的Bcl-2表达增加,均有统计学差异。结论：健脾化痰法可以对抗氧化应激和内毒素血症,干预JAK2/STAT3/Bcl-2途径,可能具有控制肥胖人群罹患肝病的作用。
Objective： To study effects of Xiangsha Liujun Pills（ XLP） on expressions of JAK2,STAT3 and Bcl-2 in obesity rats liver tissue,attempting to explore the possibility of the principle of invigorating spleen and resolving phlegm controlling the development liver diseases in obesity. Methods： Forty male SD rats were randomly divided into the control group,spleen deficiency and phlegm-turbid group（ model group）,XLP low-dose treating group（ XLG）,XLP middle-dose treating group（ XMG） and XLP high-dose treating group（ XHG）,8 rats in each group. ELISA was used to measure glutamic-pyruvic transaminase（ GPT） and glutamic-oxalacetic transaminease（ GOP） levels in liver tissue,and serum levels of superoxide dismutase（ SOD）,malondialdehyde（ MDA） and lipopolysaccharide（ LPS） and glutathion peroxidase（ GSH-Px） activity. The immunohistochemistry was used to observe phosphorylated（ p）-JAK2,p-STAT3 and Bcl-2 expressions in liver tissue. Results： Compared with those in the control,SOD level,GSH-Px activity and Bcl-2 expression were decreased,but levels of MDA,LPS,GTP and GOP,and p-JAK2/STAT3 expressions were increased significantly in the model group. Compared with those in the model group,SOD levels and GSH-Px activity were increased,but LPS level was decreased significantly in later 3 groups. MDA level and p-STAT3 expression in later2 groups were markedly reduced. GOT level in XLG was obviously decreased. The p-JAK2 and Bcl-2 expressions in XHG were significantly reduced and increased. Conclusion： The principle of invigorating spleen and resolving phlegm might control the development of liver diseases in obesity people via resisting oxidative stress and endotoxima and interpreting JAK2/STAT3/Bcl-2 pathway.
作者
王金曦
于婷婷
郑舒馨
胡世隆
包程公
单德红
WANG Jinxi;YU Tingting;ZHENG Shuxin;ZHENG Shilong;BAO Chenggong;SHAN Dehong(Liaoning University of Traditional Chinese Medicine,Shenyang 110847,Liaoning,China)
出处
《中华中医药学刊》
CAS
北大核心
2018年第9期2153-2155,共3页
Chinese Archives of Traditional Chinese Medicine
基金
国家重点基础研究发展计划(973计划)项目(2013CB531702)
辽宁省大学生创新创业训练计划项目(辽教办发2014[79号])
关键词
香砂六君丸
健脾化痰
肝
JAK2
STAT3
Bcl-2
Xiangsha Liujun Pills
invigorating spleen and resolving phlegm
liver
JAK2
STAT3
Bcl- 2
